pc:remep

Remepy

New York, NY, US

https://www.remepy.com/

Remepy develops hybrid drugs—therapeutic assets that combine conventional pharmaceutical agents with proprietary non‑pharmaceutical treatment protocols. The company applies AI-driven measurement and adaptation to deliver and optimize those protocols, operating at the intersection of drug development, digital therapeutics, and treatment personalization.

Leadership & Board

Current Number of Employees74

Current LinkedIn Followers6,372

Latest Estimated Valuation

Estimated Valuation―

Estimated Valuation―

Total Amount Raised$10M

Total Amount Raised$10M

Total Funding Rounds1

Total Funding Rounds1

Latest Funding Amount$10M

Latest Funding Amount$10M

Latest Funding RoundSeed Round

Latest Funding RoundSeed Round

Post-Money Valuation―

Post-Money Valuation―

Funding Round

Jun 01, 2024

Seed Round

$10.00M

―

Investors

Seed Round

Related News and Analysis

Remepy Highlights Positive Phase IIa Results for Hybridopa in Parkinson’s Disease

Remepy Highlights Positive Phase IIa Results for Hybridopa in Parkinson’s Disease

According to a recent LinkedIn post from Remepy, the company is highlighting Phase IIa data for Hybridopa, its...

2d ago

Remepy Highlights Positive Phase IIa Results for Hybridopa in Parkinson’s Disease

Remepy Highlights Positive Phase IIa Results for Hybridopa in Parkinson’s Disease

According to a recent LinkedIn post from Remepy, the company is highlighting Phase IIa clinical data for Hybridopa,...

3d ago

Remepy Advances Hybrid Parkinson’s Therapy as Phase IIa Trial Hits Key Milestones

Remepy Advances Hybrid Parkinson’s Therapy as Phase IIa Trial Hits Key Milestones

New updates have been reported about Remepy. Remepy has reported that its Phase IIa trial of Hybridopa, a...

3d ago

Remepy Targets 2026 Phase 3 Trial for Parkinson’s Candidate Hybridopa

Remepy Targets 2026 Phase 3 Trial for Parkinson’s Candidate Hybridopa

According to a recent LinkedIn post from Remepy, the company plans to participate in the upcoming World Parkinson...

3d ago

Remepy Prepares Phase 3 Trial of Hybridopa for Parkinson’s Disease

Remepy Prepares Phase 3 Trial of Hybridopa for Parkinson’s Disease

According to a recent LinkedIn post from Remepy, the company plans to participate in the upcoming World Parkinson...

4d ago

Remepy Partners with Merck KGaA to Scale Hybrid Drug Platform in Rare Tumors

Remepy Partners with Merck KGaA to Scale Hybrid Drug Platform in Rare Tumors

New updates have been reported about Remepy. Remepy has entered a collaboration with Merck KGaA, Darmstadt, Germany to...

16d ago

Classiq Highlights Participation in 2026 Quantum Informatics Spring School

Classiq Highlights Participation in 2026 Quantum Informatics Spring School

According to a recent LinkedIn post from Classiq, the company plans to participate in the Quantum Informatics CDT...

54s ago

Cashfree Payments Deepens Reach in Indian Retail Through Jumbotail Tie-Up

Cashfree Payments Deepens Reach in Indian Retail Through Jumbotail Tie-Up

A LinkedIn post from Cashfree Payments highlights a new relationship with Jumbotail, a platform focused on empowering local...

59s ago

Growth in Tea-Based Beverages Signals Rising Demand on HungryPanda Platform

Growth in Tea-Based Beverages Signals Rising Demand on HungryPanda Platform

According to a recent LinkedIn post from HungryPanda, the company is observing a rapid shift in the U.S....

59s ago

Fractal Emphasizes Talent Pipeline With Hands-On AI and Analytics Internship Program

Fractal Emphasizes Talent Pipeline With Hands-On AI and Analytics Internship Program

A LinkedIn post from Fractal highlights the arrival of a new cohort of summer interns, described as being...

1m ago